Mineralys publishes positive Phase 2 lorundrostat kidney-disease data in Kidney International

What's the deal? Mineralys Therapeutics announced on 28 October 2026 that full results from its Phase 2 Explore-CKD trial of lorundrostat have been published in the journal Kidney International. The trial met its primary endpoint: in 59 adults with difficult-to-control high blood pressure, chronic kidney disease (CKD) stages 1-3b and albuminuria (protein leaking into the urine, an early sign of kidney damage), adding lorundrostat 25 mg once daily to an SGLT2 inhibitor - a standard kidney-protective medicine - lowered systolic blood pressure by 7.5 mmHg more than placebo at four weeks (9.3 vs 1.8 mmHg reduction; p=0.0024).

Why it matters: Lorundrostat is an aldosterone synthase inhibitor - it blocks production of aldosterone, a hormone that drives salt retention, blood pressure and kidney scarring. Around 76% of people with both CKD and high blood pressure do not reach blood-pressure targets on multiple existing drugs, and CKD is strongly linked to heart disease. Beyond the blood-pressure effect, lorundrostat also reduced albuminuria, which the company says may point to a direct kidney benefit. The drug is already in later-stage testing: the pivotal Phase 3 Launch-HTN trial in uncontrolled hypertension met its endpoints, and a US FDA decision on lorundrostat's New Drug Application is expected; new data were also presented at ASN Kidney Week 2026.

Read more: Mineralys Therapeutics, 28 October 2026